What is Akili Interactive?
Founded in 2011 and headquartered in Boston, Akili Interactive operates at the vanguard of the digital health revolution. The company specializes in the development of FDA-cleared digital therapeutics, utilizing proprietary gaming platforms to deliver clinical-grade cognitive interventions. By bridging the gap between traditional medical treatments and interactive software, Akili provides scalable, evidence-based solutions for patients suffering from various neurological and psychiatric conditions. Their business model encompasses both direct-to-consumer digital health offerings and strategic partnerships with healthcare providers, ensuring a comprehensive approach to patient care and cognitive health management.
How much funding has Akili Interactive raised?
Akili Interactive has raised a total of $296.4M across 6 funding rounds:
Series A
$8.5M
Private Equity
$30.5M
Series B
$42.4M
Series C
$55M
Debt
$50M
Series D
$110M
Series A (2012): $8.5M, investors not publicly disclosed
Private Equity (2016): $30.5M led by PureTech Health, JAZZ Venture Partners, and Canepa Advanced Healthcare Fund
Series B (2016): $42.4M supported by Amgen Business Development and Merck Ventures BV
Series C (2018): $55M featuring Amgen Business Development, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, Baillie Gifford, Brooklands Capital Strategies, M Ventures, and Temasek
Debt (2021): $50M backed by Silicon Valley Bank
Series D (2021): $110M with participation from New Leaf Venture Partners, Neuberger Berman Funds, Shionogi & Co, Mirae Assets, and Polaris Partners
Key Investors in Akili Interactive
Temasek
A global investment company headquartered in Singapore that acts as a generational investor with a long-term focus on transformative technologies.
M Ventures
The strategic corporate venture capital arm of Merck, focusing on early-stage investments and company creation to drive innovation in core business areas.
New Leaf Venture Partners
A venture capital firm dedicated to funding innovative healthcare companies and supporting transformative technologies that improve patient outcomes.
What's next for Akili Interactive?
Looking ahead, the recent capital injection is expected to accelerate the commercialization of Akili's digital therapeutic pipeline and support the expansion of its clinical research initiatives. As the company transitions into its next phase of growth, the focus will likely shift toward deepening market penetration and exploring new therapeutic indications for its software-based treatments. The strategic backing from institutional investors and healthcare-focused venture firms provides the necessary runway to navigate the evolving regulatory landscape and scale operations globally. By maintaining its commitment to rigorous clinical validation, Akili Interactive is well-positioned to redefine the standard of care in the digital medicine market, potentially setting new benchmarks for efficacy and patient engagement in the healthcare technology sector.
See full Akili Interactive company page
